CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma is a primary bone cancer common in children and adolescents.
• Cluster of differentiation 44 (CD44) is a cell-surface glycoprotein implicated in cell adhesion and migration.
• Understanding CD44's role is crucial for advancing osteosarcoma treatment.

Purpose of the Study:

• To investigate the expression and role of CD44 in osteosarcoma.
• To explore the relationship between CD44, microRNA-199a-3p (miR-199a-3p), and osteosarcoma progression.
• To assess the therapeutic potential of targeting the CD44-miR-199a-3p axis.

Main Methods:

• Construction of a human osteosarcoma tissue microarray with 114 patient samples.
• Immunohistochemistry to determine CD44 expression levels.
• In vitro studies involving osteosarcoma cell lines to analyze miR-199a-3p's effect on CD44 expression and drug sensitivity.

Main Results:

• CD44 was significantly overexpressed in metastatic and recurrent osteosarcoma compared to primary tumors.
• Higher CD44 expression correlated with shorter patient survival and poor response to neoadjuvant chemotherapy.
• miR-199a-3p directly targets CD44 mRNA, and its restoration inhibited CD44 expression and enhanced drug sensitivity in osteosarcoma cells.

Conclusions:

• The CD44-miR-199a-3p axis is pivotal in osteosarcoma metastasis, recurrence, and chemoresistance.
• Downregulation of miR-199a-3p contributes to CD44 overexpression in osteosarcoma.
• Targeting CD44 presents a promising therapeutic strategy for improving clinical outcomes in osteosarcoma patients.